Skip Navigation


Carcinogenesis Advance Access originally published online on May 27, 2004
Carcinogenesis 2004 25(10):1829-1838; doi:10.1093/carcin/bgh192
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
25/10/1829    most recent
bgh192v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Pandey, J.
Right arrow Articles by Wendell, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pandey, J.
Right arrow Articles by Wendell, D. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.25 no.10 © Oxford University Press 2004; all rights reserved.

ARTICLE

The Edpm5 locus prevents the ‘angiogenic switch’ in an estrogen-induced rat pituitary tumor

Jyotsna Pandey, Anas Bannout and Douglas L. Wendell1

Department of Biological Sciences, Oakland University, Rochester, MI 48309, USA

1 To whom correspondence should be addressed Email: wendell{at}oakland.edu

Edpm5 is one member of a group of quantitative trait loci that are responsible for the difference in susceptibility to estrogen-induced prolactinoma between the Fischer 344 (F344) and Brown Norway (BN) strains. Upon chronic estrogen treatment F344 rats develop large, hemorrhagic and invasive pituitary tumors, which exhibit both tumor angiogenesis and neoplasia. In contrast, BN rats do not develop a tumor despite an estrogen-induced increase in lactotroph density. To investigate the role of Edpm5 in the development of these tumors, we have generated a novel congenic rat strain F344.BN-Edpm5BN by introgressing the segment of rat chromosome bearing Edpm5 from BN into the F344 strain background. Phenotypic differences between F344 and F344.BN-Edpm5BN must be due to a gene(s) within the chromosomal interval encompassing Edpm5. Through use of these strains, we find that Edpm5 specifically regulates the switch to angiogenic phenotype, independent of neoplasia. The F344.BN-Edpm5BN rats developed tumors, which exhibited significant growth, 7-fold greater mass than the pituitary of untreated rats, and neoplasia indistinguishable from that of the F344 strain. However, the F344.BN-Edpm5BN rat tumor had a non-angiogenic phenotype. After chronic estrogen treatment, there was no increase in microvessel count over untreated controls in F344.BN-Edpm5BN tumors, whereas F344 rat tumors showed a significant increase (P < 0.0005). The ultrastructural morphology of the pituitary blood vessels also did not show significant angiogenesis associated changes in F344.BN-Edpm5BN rat pituitary tumors. In contrast the parental strain F344 had pronounced angiogenic activity. The F344.BN-Edpm5BN strain also fails to express VEGF at the high levels seen in the F344 rat pituitary after estrogen treatment. Hence at least one gene that has a large impact, directly or indirectly, on the switch to angiogenic phenotype must reside within the chromosomal interval that is the Edpm5 quantitative trait locus.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
S. G. Kurz, K. K. Hansen, M. T. McLaughlin, V. Shivaswamy, B. S. Schaffer, K. A. Gould, R. D. McComb, J. L. Meza, and J. D. Shull
Tissue-Specific Actions of the Ept1, Ept2, Ept6, and Ept9 Genetic Determinants of Responsiveness to Estrogens in the Female Rat
Endocrinology, August 1, 2008; 149(8): 3850 - 3859.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. Pandey, S. M. Umphress, Y. Kang, J. Angdisen, A. Naumova, K. L. Mercer, T. Jacks, and S. B. Jakowlew
Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- 1 haploinsufficiency
Carcinogenesis, December 1, 2007; 28(12): 2589 - 2596.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
N. L. Ward, E. Moore, K. Noon, N. Spassil, E. Keenan, T. L. Ivanco, and J. C. LaManna
Cerebral angiogenic factors, angiogenesis, and physiological response to chronic hypoxia differ among four commonly used mouse strains
J Appl Physiol, May 1, 2007; 102(5): 1927 - 1935.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Gurlek, N. Karavitaki, O. Ansorge, and J. A H Wass
What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics
Eur. J. Endocrinol., February 1, 2007; 156(2): 143 - 153.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
P. van Wijngaarden, D. J. Coster, H. M. Brereton, I. L. Gibbins, and K. A. Williams
Strain-Dependent Differences in Oxygen-Induced Retinopathy in the Inbred Rat
Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1445 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 GeneticsHome page
T. E. Strecker, T. J. Spady, B. S. Schaffer, K. A. Gould, A. E. Kaufman, F. Shen, M. T. McLaughlin, K. L. Pennington, J. L. Meza, and J. D. Shull
Genetic Bases of Estrogen-Induced Pituitary Tumorigenesis: Identification of Genetic Loci Determining Estrogen-Induced Pituitary Growth in Reciprocal Crosses Between the ACI and Copenhagen Rat Strains
Genetics, April 1, 2005; 169(4): 2189 - 2197.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.